Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma?

G. d'Ancona (London, United Kingdom), L. Green (London, United Kingdom), M. Fernandes (London, United Kingdom), C. Roxas (London, United Kingdom), L. Osman (London, United Kingdom), K. Stewart-Knight (London, United Kingdom), J. Kavanagh (London, United Kingdom), A. Nanzer-Kelly (London, United Kingdom), D. Jackson (London, United Kingdom), B. Kent (London, United Kingdom)

Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Session: Real-world experience of monoclonal antibodies in asthma
Session type: Thematic Poster
Number: 2526
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. d'Ancona (London, United Kingdom), L. Green (London, United Kingdom), M. Fernandes (London, United Kingdom), C. Roxas (London, United Kingdom), L. Osman (London, United Kingdom), K. Stewart-Knight (London, United Kingdom), J. Kavanagh (London, United Kingdom), A. Nanzer-Kelly (London, United Kingdom), D. Jackson (London, United Kingdom), B. Kent (London, United Kingdom). Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma?. 2526

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: